Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Nasdaq Inc (NDAQ) vs Novartis AG (NVS) Price & Performance

Nasdaq IncTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

Nasdaq Inc vs Novartis AG — how do they compare? Nasdaq Inc trades at $95.64 (market cap $53.11B), while Novartis AG trades at $152.59 (market cap $295.37B). The key difference: Novartis AG is far larger — about 5.6× Nasdaq Inc's market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.

NDAQNVS
Market Cap
$53.11B$295.37B
Sector
FinancialsHealth
52-Week High
$100.98$168.62
52-Week Low
$76.85$119.31
Enterprise Value
$59.57B$336.69B
Dividend Yield
1.22%3.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nasdaq Inc

Nasdaq (NDAQ) trades at $95.26, down 0.38% on the day, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $8.26B in 2025, with net income reaching $1.79B and a profit margin of 21.64%. The company has beaten EPS estimates in recent quarters and announced the acquisition of LeveL Markets to expand its market infrastructure. Analyst consensus is strongly positive, with a $109.20 price target indicating ~15% upside.

Outlook remains favorable driven by earnings growth and strategic acquisitions, though risks include market volatility and integration challenges. The stock offers value through consistent profitability and dividend payments, supported by institutional confidence. Investors should weigh execution risks against the potential for continued expansion in financial services technology.

Novartis AG

Novartis AG (NVS) trades at $152.54, down 2.71% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates of $2.17 with $2.41 actual, driven by oncology drug performance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%. Analyst consensus is mixed with 24% buy, 68% hold, and 8% sell ratings among 25 analysts.

The outlook is cautiously optimistic, supported by a robust drug pipeline and recent earnings strength, but risks include generic competition pressure on key drugs like Entresto and rising debt levels. The stock presents a stable investment opportunity with solid profitability, though growth may be tempered by industry headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Nasdaq Inc

Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.

Read more on NDAQ

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS